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Lesions displaying a variety of dysplastic changes pre-
cede invasive oral and epidermal squamous cell carci-
noma (SCC); however, there are no histopathological
criteria for either confirming or staging premalignancy.
SCCs and dysplasias frequently contain cells that abnor-
mally express the 2 subunit of laminin-332. We devel-
oped cell culturemodels to investigate 2 dysregulation.
Normal human keratinocytes displayed density-depen-
dent repression of 2, whereas premalignant keratino-
cytes and SCC cells overexpressed 2 and secreted
laminin assembly intermediates. Neoplastic cells had
hyperactive EGFR/MAPK(ERK) signaling coordinate
with overexpressed 2, and EGFR and MEK inhibitors
normalized 2 expression. Keratinocytes engineered to
express HPV16 E6 or activated mutant HRAS, cRAF1, or
MEK1 lost density repression of 2 and shared with
neoplastic cells signaling abnormalities downstream of
ERK, including increased phosphorylation of S6 and
eIF4 translation factors. Notably, qPCR results revealed
that2overexpressionwasnot accompaniedby increased
2 mRNA levels, consistent with ERK-dependent, eIF4B-
mediated translation initiation of the stem-looped, 5=-un-
translated region of 2 mRNA in neoplastic cells. Inhibi-
tors of MEK, but not of TORC1/2, blocked S6 and eIF4B
phosphorylation and 2 overexpression. Immunostain-
ing of oral dysplasias identified 2 overexpression oc-
curring within fields of basal cells that had elevated p-S6
levels. These results reveal a causal relationship be-
tween ERK-dependent translation factor activation
and laminin 2 dysregulation and identify new mark-
ers of preinvasive neoplastic change during progres-
sion to SCC. (Am J Pathol 2012, 180:2462–2478; http://dx.
doi.org/10.1016/j.ajpath.2012.02.028)
2462Squamous cell carcinoma (SCC) is a major cancer that
arises from stratified epithelia, including the oral epithe-
lium, epidermis, and the epithelia covering the orophar-
ynx, esophagus, tracheobronchus, bladder, vulva, and
cervix. Among attributes shared by the normal basal cells
of these epithelia are synthesis of the basement mem-
brane protein laminin-332 (Lam332) (previously known as
laminin 5) and control of their cell division by EGF.1,2
Approximately 300,000 new cases of SCC per year occur
in the United States, resulting annually in 100,000
deaths.3,4 Depending on the tissue of origin, the carcino-
genic instigator is chronic exposure to UV radiation (epi-
dermis), tobacco (oral and lung), industrial or environ-
mental carcinogens (lung and bladder), or infection with
papillomaviruses HPV16/18 (cervix, some vulva, some
oropharynx).5–8 Abnormal hyperactivity of the EGFR/ERK
and the PI3K/AKT/mTOR signaling pathways are typical
characteristics of advanced SCC.9–11 If not excised at an
early stage, SCCs infiltrate deeply and spread rapidly by
colonizing regional lymph nodes, such that they can no
longer be completely surgically resected. SCCs of all
tissue origins have proven refractory to nonsurgical treat-
ment regimens, including small-molecule kinase inhibi-
tors.12–15 Annually in the United States there are 20,000
new cases of oral SCC and 40,000 head and neck SCCs
(combined total for oral and oropharynx SCCs). Five-year
survival after diagnosis of head and neck SCC is 50%,
which has remained unchanged for many decades, re-
gardless of treatment protocols.3,16
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AJP June 2012, Vol. 180, No. 6Visual accessibility of the oral cavity has led to the iden-
tification of potential precursor lesions to SCC. Such lesions
appear more white, more red, or more scaly than normal
epithelium. The incidence of oral lesions is high, at approx-
imately 1% to 3% in adults.17 Some of these lesions even-
tually disappear, whereas others progress to invasive SCC.
It is estimated that, in the United States and Europe, oral
dysplasias progress to SCC at a rate of 2% to 6% per
year.17–20 Microscopically, many of these lesions show
signs of dysplasia, including abnormal cell and nuclear
shape and delay of suprabasal differentiation.21,22 There
remains much uncertainty about the criteria for a diagnosis
of premalignant dysplasia and whether any feature of dys-
plastic change predicts future progression to SCC,20,23,24
so the need to identify prognostic biomarkers is urgent.
In an earlier study,25 we detected coordinate induction of
p16INK4A and overexpression of laminin 2 (Lam2) in some
oral and epidermal dysplasias, occurring at greater fre-
quency in dysplasias of higher degrees of atypia and at
margins of invasive SCC. Lam2 and the two partner sub-
units laminin 3 and laminin 3 form Lam332. After intracel-
lular assembly of the three subunits, normal basal epithelial
cells secrete the Lam332 trimer, proteolytically process it,
and deposit it into the underlying basal lamina, where it
serves as an essential component of hemidesmosomes,
conferring stable, polarized epithelial cell adhesion.2 After
tissue development is complete, basal keratinocytes stop
synthesizing immunohistochemically detectable amounts of
Lam2.25,26 Invading carcinoma cells, however, frequently
reinitiate high rates of Lam2 synthesis.27–29 Because ab-
Table 1. Human Cell Lines Used in This Study
Cell line
Donor sex
(age)*
Epidermal keratinocyte
Strain N M (0) Normal
N/HPV16E6E7 M (0) Immortal; p5
N/HPV16E6 M (0) All E6 functi
N/HPV16E6 (JH26 mutant) M (0) p53 normal
N/HPV16E7 M (0) All E7 functi
N/p53DD/cdk4R24C M (0) p53-deficien
N/TERT1 M (0) Immortal; los
N/TERT1/EGFR (E746-A750) M (0) Immortal; EG
N/TERT1/HRAS (G12V) M (0) Immortal; EG
N/TERT1/cRAF1 (22W) M (0) Immortal; EG
N/TERT1/MEK1 (DD) M (0) Immortal; EG
G5Ep M (0) Normal
O5Ep M (0) Normal
Epidermal SCC
SCC-13 F (56) p16- and p5
Oral keratinocyte
OKF6 M (57) Normal
Dysplastic oral keratinocyte
POE9n M (65) Homozygou
nontumori
D17 ND (ND) p16INK4A-de
Oral SCC
SCC-15 M (55) p16- and p5
SCC-25 M (74) p16- and p5
SCC-68 M (ND) p16- and p5
SCC-71 M (80) p16- and p5
*Ages are given in years; 0 indicates newborn.
†References for derivation and characterization of previously published cell l
F, female; M, male; ND, no data.normal Lam2 expression begins in premalignant lesions,25
its immunohistologic detection has potential as a prognostic
marker for lesions at high risk for progression to SCC. De-
termining the mechanism of neoplastic Lam2 dysregula-
tion could identify ancillary prognostic markers and poten-
tial targets for early-intervention drug therapy.
We have identified a human cell culture model system
that recapitulates the in vivo situation of Lam2 repression
by normal keratinocytes and overexpression by prema-
lignant and malignant keratinocytes. Using this system,
we have identified EGFR/MAPK(ERK)-pathway hyperac-
tivation as the driver of Lam2 overexpression by neo-
plastic cells, correlated with increased phosphorylation
and activation of the translation factors S6 and eIF4B. Our
data reveal that neoplastic Lam2 expression is the result
of increased translation, not transcription. We find that in
oral dysplasias in vivo, Lam2 overexpression occurs
strictly within fields of basal cells that have abnormally
increased levels of p-S6. These results serve to define a
new, immunohistologically detectable stage of neoplastic
progression in preinvasive dysplasias.
Materials and Methods
Cells and Cell Culture
The cell lines used are characterized in Table 1 and in the
articles cited therein.1,30–39 Derivation and use of these
cell lines were IRB-approved. The premalignant oral ke-
Special characteristics References†
1, 30–33
pRb-deficient 1, 31
cluding p53-deficiency
other E6 functions
cluding Rb-deficiency 30
16INK4A-resistant 34
ility to express p16INK4A and p14ARF 1, 30, 31
pendent for growth
pendent for growth; Lam2 overexpressing
pendent for growth; Lam2 overexpressing
pendent for growth; Lam2 overexpressing
35
ient; immortal; tumorigenic 31–33, 36, 37
30
ion of p16INK4A and p14ARF; p53-deficient, 30, 31
normal p53; nontumorigenic 38, 39
ient; immortal; tumorigenic 32, 36, 37
ient; immortal; tumorigenic 32, 36, 37
ient; immortal; tumorigenic
ient; immortal; tumorigenic 31, 363- and
ons, in
but has
ons, in
t and p
s of ab
F-inde
F-inde
F-inde
F-inde
3-defic
s delet
genic
ficient;
3-defic
3-defic
3-defic
3-deficines.
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kinson (Queen Mary University of London, UK). Cells
were cultured in keratinocyte serum-free medium (Ksfm)
(Invitrogen; Life Technologies, Carlsbad, CA) with 25
g/mL bovine pituitary extract, 0.2 ng/mL epidermal
growth factor (EGF), and CaCl2 to a final Ca
2 concen-
tration of 0.4 mmol/L, as described previously.30 To main-
tain healthy confluent cultures, after cultures reached
40% confluence in Ksfm they were refed daily with 1:1
medium (1:1 vol/vol Ca2-free Dulbecco’s modified Ea-
gle’s medium from Invitrogen with Ksfm and supple-
mented as described above for Ksfm alone), as de-
scribed previously.1 To avoid variation among cell lines
with respect to stratification and differentiation, cultures
approaching confluence were fed with 1:1 medium with
0.1 mmol/L CaCl2. To assess EGF-dependent growth,
2000 cells per 9-cm2 well were plated with or without
EGF, refed every 2 to 3 days, and counted 6 to 8 days
later. Average growth rate in terms of population dou-
blings (PD) per day was calculated as log2(number of
cells obtained at subculture/number of cells plated)/num-
ber of days cultured.
Protein Extracts and Conditioned Medium
Samples
To analyze laminin protein expression in cells, cultures
were suspended with trypsin/EDTA and lysed in protein
extraction buffer consisting of 20 mmol/L Tris-HCl (pH
7.3), 2% SDS, EDTA-free protease inhibitor cocktail
(Roche, Indianapolis, IN), and phosphatase inhibitor
cocktail (Thermo Scientific, Rockford, IL). Alternatively,
cultures were rinsed twice with PBS, drained, and lysed
in protein extraction buffer to obtain both intracellular
proteins and proteins that had been deposited onto the
culture dish (matrix proteins). Extracts were sonically dis-
rupted and stored at 80°C. The BCA protein assay
(Thermo Scientific) was used to measure protein concen-
trations. For phosphoprotein analysis, cultures were
lysed in reducing Laemmli SDS sample buffer.40 To an-
alyze secreted laminin, conditioned medium of cultures
was collected 24 hours after refeeding, passed through
0.2-m filters, and stored at 80°C. After conditioned
medium harvest, cultures were trypsinized and their pro-
teins were extracted and measured to normalize loading
volumes of conditioned medium samples for comparative
Western blot analysis.
Western Blotting
Protein (20 g per lane) in Laemmli sample buffer was
separated by SDS-PAGE under reducing or nonreducing
conditions on 4% to 20% gradient gels (Bio-Rad Labora-
tories, Hercules, CA), blotted to polyvinyl difluoride mem-
branes (Bio-Rad Laboratories), blocked for 1 hour with
5% nonfat milk in Tris-buffered saline with 0.05% polysor-
bate 20 (Tween 20), incubated overnight with primary
antibody, rinsed, and incubated for 1 hour with peroxi-
dase-conjugated anti-rabbit or anti-mouse IgG (1:2000)
(Dako, Glostrup, Denmark) at room temperature. Blotswere developed using ECL (Roche) or SuperSignal West
Femto chemiluminescent substrate (Thermo Scientific)
and exposed to HyBlot CL autoradiography film (Denville
Scientific, Metuchen, NJ).
Some Lam2 Western blots were analyzed densito-
metrically using ImageJ software version 1.45 (NIH, Be-
thesda, MD; http://rsbweb.nih.gov/ij). Two different film
exposure times were analyzed. The total intensity of each
Lam2 band was normalized to the actin band intensity of
the same extract and film exposure time.
Antibodies
The murine monoclonal antibodies used were laminin 2
(clone D4B526; Chemicon, Billerica MA), laminin 3
(clone 12C4,41 provided by Jonathan Jones, Northwest-
ern University, Chicago, IL), laminin 3 (clone 17) and
c-myc (clone 9E10; BD Transduction Laboratories,
Franklin Lakes, NJ), p53 (clone DO-1; Santa Cruz Bio-
technology, Santa Cruz, CA), EGFR (clone 1F4; Cell Sig-
naling Technology, Danvers, MA), and FLAG (clone M2;
Sigma-Aldrich, St. Louis, MO). The rabbit monoclonal
antibodies used were p-eIF4E(Ser209) (clone EP2151Y)
from EMD Millipore (Billerica, MA) and p-AKT(Ser473)
(clone D9E), p-S6(ser235/236) (clone 91B2), and
p-EGFR(Tyr1068) (clone D7A5) from Cell Signaling Tech-
nology. The rabbit polyclonal antibodies used were -ac-
tin (A-2066; Sigma-Aldrich), p-eIF4B(Ser422) (Abcam,
Cambridge, MA), and ERK1/2, p-ERK1/2(Thr202/Tyr204),
and p-4E-BP1(Ser65) (Cell Signaling Technology).
Signaling Pathway Inhibitors
The TGF receptor I kinase inhibitor TRI (discovered inde-
pendently as Biogen HTS466284 and Lilly LY364947) was
used at 1 mol/L (EMD Millipore Chemicals, Gibbstown,
NJ).31,42 The EGFR inhibitor gefitinib43,44 (provided by Pasi
Janne, Dana-Farber Cancer Institute) was used at 1mol/L.
The MEK inhibitors AZD624445 (Selleck Chemicals, Hous-
ton, TX) and U012646 (Cell Signaling Technology) were
used at 100 nmol/L and 1 mol/L, respectively. The
mTORC1/2 inhibitor Ku-006379447,48 (Chemdea, Ridge-
wood, NJ) was used at 500 nmol/L. The ERK inhibitor
CAY1056149 (Cayman Chemical, Ann Arbor, MI) and the
RSK inhibitor BI-D187050 (Symansis, Auckland, NZ) were
each used at 1 mol/L. The translation inhibitor cyclohex-
imide (Sigma-Aldrich) was used at 10 g/mL and the
protein transport inhibitor brefeldin A (BD Biosciences,
San Jose, CA) at 1 g/mL. Inhibitors were added to the
medium at plating and each refeeding from 1000 con-
centrated solutions in dimethyl sulfoxide, stored frozen
between uses.
Immunofluorescence Staining
Cultures were rinsed, fixed, stored in 100% methanol at
20°C, and air-dried before use. After 15 minutes of
blocking in PBS with 10% goat serum (Invitrogen), pri-
mary antibodies diluted in PBS with 0.1% BSA were ap-
plied for 1 hour at room temperature. Cultures then were
rinsed with PBS, incubated with fluorescent-labeled sec-
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coverslip-mounted with ProLong Gold antifade mounting
medium with DAPI (Invitrogen). Cells were examined un-
der an inverted Nikon Eclipse Ti fluorescence micro-
scope fitted with an RT-slider SPOT camera (SPOT Im-
aging Solutions, Sterling Heights, MI).
Tissue Samples, Immunohistochemical Staining,
and Quantification
Selection and diagnosis of a set of 26 formalin-fixed,
paraffin-embedded, lateral tongue tissue specimens
from the University of Connecticut Oral Pathology archi-
val collection was performed with IRB approval by an
expert oral pathologist (E.N.). The cohort included normal
epithelium, benign warts, dysplasias, and microinvasive
to advanced SCCs.
Paraffin sections (5 m thick) on slides were warmed
to 37°C for 30 minutes, then deparaffinized and hydrated
through xylene, ethanol, and PBS; to better preserve an-
tigens, slides were not baked at 50°C after sectioning, as
is a common practice of histopathology labs.25 Antigen
retrieval was performed in 10 mmol/L sodium citrate buf-
fer (pH 6.0) autoclaved for 15 minutes. Endogenous per-
oxidase was inactivated by incubating slides in 0.3%
H2O2 in methanol for 10 minutes. After a PBS rinse, slides
were blocked with PBS with 10% horse serum (Invitro-
gen) for 20 minutes, incubated with primary antibody for
1 hour at room temperature, biotinylated secondary anti-
body (1:100) for 1 hour, and avidin/biotin/peroxidase
complex (ABC) reagent (Vectastain Elite ABC kit; Vector
Laboratories, Burlingame, CA) for 45 minutes, with three
PBS rinses between each step. Slides were incubated
with Vector Red (Vector Laboratories) for 1 to 5 minutes,
the reaction was stopped by rinsing in water, and slides
were coverslip-mounted with Fluoromount-G mounting
medium (SouthernBiotech, Birmingham, AL). Slides were
examined under a Nikon Eclipse TE2000-S microscope
and were photographed as described above.
Twenty-one dysplasia specimens for which sequential
sections were stained for Lam2 and p-S6 were quanti-
fied for percentage basal p-S6 and Lam2 expression.
The total length of dysplastic areas in each specimen
was determined by examining an adjacent H&E-stained
slide, and the proportion of the dysplastic region contain-
ing p-S6 and Lam2 basal cells was determined.
Retroviral Vectors and Transduction
Retroviral vector plasmids pBABE.puro/EGFR(E746-
A750)-FLAG, [EGFR (746–750) retroviral vector was
provided by Dr. Pasi Janne (Dana Farber Cancer Insti-
tute, Boston)],43 pBABE.puro/cRAF-1(22w),51,52 pLHCX/
MEK1(S218D,S222D) [MEK1(DD)],53,54 pBABE.puro/HRAS
(G12V),55,56 pL(HPV16E6)SN [HPV16E6 retroviral vector
was provided by Dr. Denise Galloway (Fred Hutchinson
Cancer Center, Seattle)],57 and pL(E6(JH26))SN58–60
[HPV16E6(JH26) retroviral vector was provided by Drs.
Karl Munger and Peter Howley (Harvard Medical School,
Boston)] were transfected into Phoenix packaging cells61using TransIT-LT1 transfection reagent (Mirus Bio, Mad-
ison, WI). Retroviral supernatants were collected in 1:1
medium (as above) at 8- to 16-hour intervals from 1 to 3
days after transfection, passed through 0.45-m pore
filters, and stored at80°C. Cells plated 1 day previously
at 105 cells/9 cm2 well in Ksfm were transduced for 6 to
7 hours with retroviral supernatants containing 2 g/mL
polybrene (Sigma-Aldrich), as described previously.30
Transduced cells were subcultured the next day into
p100 tissue culture dishes with Ksfm containing 15
g/mL hygromycin, 1 g/mL puromycin, or 0.2 mg/mL
G418 and drug-selected for 5 to 7 days to obtain pure
populations of stable transductants.
Quantitative PCR
Total RNA was isolated from cells using an RNeasy Plus
mini kit (Qiagen, Valencia, CA) and cDNA synthesized
from 500 ng total RNA using the iScript cDNA synthesis
kit (Bio-Rad Laboratories). mRNA levels were quantified by
quantitative real-time PCR (qPCR) using Applied Biosys-
tems (ABI) FAST SYBR Green PCR master mix (Life Tech-
nologies, Foster City, CA) on an ABI StepONE Plus instru-
ment (40 cycles of 95°C for 15 seconds and 58°C for 30
seconds). Amplicons were as follows: laminin 2 (LAMC2
gene), forward 5=-CTCTGCTTCTCGCTCCTCC-3= and re-
verse 5=-TCTGTGAAGTTCCCGATCAA-3=; laminin 3
(LAMA3), forward 5=-TCAGCACATATTATCTGGGAGG-3=
and reverse 5=-AAATTTTTCATGCAGCCTCG-3=; laminin 3
(LAMB3), forward 5=-CCAAGCCTGAGACCTACTGC-3=
and reverse 5=-GCCACATTCTCTACTCGGTGA-3=); and
GAPDH, forward 5=-GAGCCTCAAGATCATCAGCA-3= and
reverse 5=-ACAGTCTTCTGGGTGGCAGT-3=). Relative ex-
pression was calculated using the CT method, normaliz-
ing values to GAPDH within each sample; standard error of
the mean was calculated from the results of triplicate ali-
quots.
Results
A Human Cell Culture Model of Neoplastic
Laminin 2 Overexpression
Our earlier study that found abnormal Lam2 expression
in oral and epidermal dysplasias25 extended previous
reports that Lam2 is frequently expressed by cells at the
invading fronts of SCC and certain other carcino-
mas.27–29 Examples of such Lam2 immunostaining pat-
terns are shown in Figure 1A. To investigate the mecha-
nism of neoplastic Lam2 overexpression, we sought to
identify culture conditions under which normal primary
keratinocytes would cease, but SCC cells would con-
tinue, expressing Lam2. Cell lines used are character-
ized in Table 1. At low cell density, both normal keratino-
cytes (G5Ep) and SCC cells (SCC-68) synthesized
Lam2 (intracellular staining) and secreted this protein
onto the culture dish (extracellular staining) (Figure 1B).
Substratum-deposited Lam2 remained stably adherent
to the culture dish for many days after secretion, as
evidenced by the equal staining intensity of Lam2 ad-
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cells (Figure 1B). (Note that during proliferation in culture
keratinocytes migrate randomly over short distances,
with the extent of this movement over the course of many
days detectable by immunostaining for the Lam332 that
the cells deposit on the substratum.31)
As normal keratinocytes grew to higher density, they
began to reduce Lam2 synthesis and at confluence no
longer expressed this protein at detectable levels (Figure
1, B and C). In contrast, SCC cells expressed Lam2 at
the same levels independent of density (Figure 1, B and
C). Lam2 previously deposited by cells onto the culture
dish remained adherent after trypsin/EDTA-detachment
of cells but was solubilized together with intracellular
protein by direct addition of SDS lysis buffer to cultures
(compare detached cell extracts with scraped extracts in
Figure 1C). The scraped extract contained both intra-
cellular, unprocessed (155 kDa) and extracellular, pro-
teolytically processed (105 kDa) forms of Lam2. West-
ern blot analysis of the conditioned medium of
confluent N/E6E7 cultures showed an increased rate of
Lam2 synthesis and secretion, similar to that of SCC
cells (Figure 1D).
To determine whether different rates of intracellular
Lam2 protein turnover contribute to the apparent differ-
ences In Lam2 expression between normal keratino-
cytes and SCC cells, we examined intracellular Lam2
stability using cycloheximide. Because Lam2 is nor-
mally secreted, we treated cells with brefeldin A, an in-
hibitor of endoplasmic reticulum-to-Golgi transport, to re-
tain the protein inside cells. Treatment with brefeldin A
alone increased intracellular Lam2, as expected (see
Supplemental Figure S1 at http://ajp.amjpathol.org). Nor-
mal and SCC cells treated with brefeldin A and cyclohex-
imide showed little or no decrease in Lam2 over 6 hours,
with no indication of a shorter half-life of the pro-
tein in normal cells (see Supplemental Figure S1 at
Figure 1. Laminin 2 overexpression by neoplastic epithelial cells in vivo
and at high cell density in culture. A: H&E-stained and Lam2-immuno-
stained sections of the margin between normal oral epithelium and a pre-
malignant dysplasia (top panels) and an invasive oral SCC (bottom
panels). Note absence of Lam2 expression in normal epithelium, in con-
trast to focal expression of Lam2 by basal cells in the dysplastic lesion and
in the SCC. Scale bar  250 m. B: Preconfluent and confluent cultures of
normal primary keratinocytes (G5Ep) and SCC cells (SCC-68) showing phase-
contrast images and the same (preconfluent) or similar (confluent) fields
immunostained for Lam2 (green fluorescence). Note substantial intracellu-
lar (endoplasmic reticulum/Golgi) Lam2 content and deposition onto the
culture dish by preconfluent normal keratinocytes and SCC cells, whereas
only the SCC cells continued to express immunodetectable Lam2 at conflu-
ence. Scale bar  50 m. C: Western blot analysis of Lam2 expression by
G5Ep and SCC-68 cells as a function of cell density. Protein extracts of
replicate cultures were harvested at cell densities indicated by the phase
contrast microscopic images shown beneath (Scale bar  500 m), either as
trypsin/EDTA-detached cell extracts (C) or scraped extracts (ie, total cell plus
extracellular matrix material) (CM). The upper band in blots is the 155-kDa
unprocessed form and the lower band is the 105-kDa postsecretion pro-
cessed form of Lam2. Note reduction of Lam2 expression by normal
keratinocytes with increasing cell density, in contrast to density-independent
expression by SCC cells.D:Harvests of conditioned medium at 24 hours from
confluent cultures of normal keratinocytes (G5Ep), premalignant keratino-
cytes (N/E6E7 and POE9n), and SCC cells (SCC-13, SCC-68) separated on a
reducing gel, Western blotted, and probed for Lam2. Note increased pro-
duction rates of Lam2 by premalignant and SCC cells, and also Lam2
processing deficiencies in POE9n, SCC-13, and SCC-68.
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tein known to have a short half-life, decreased progres-
sively in normal keratinocytes and SCC cells with time
after cycloheximide treatment (see Supplemental Figure
S1 at http://ajp.amjpathol.org). We concluded that Lam2
overexpression is the result of increased rates of synthe-
sis of this protein by SCC cells.
Unbalanced Expression of the Three Laminin-
332 Chains Results in Secretion of Laminin 2
Monomers by SCC Cells
We next examined expression of the other two Lam332
subunits, Lam3 and Lam3, to determine whether their
synthesis is differentially regulated in normal keratino-
cytes and SCC cells. Normal keratinocytes (G5Ep, O5Ep,
and strain N) at high cell density greatly reduced Lam3
expression, as well as Lam2 expression, and slightly
reduced Lam3 expression, compared with low density
cells (Figure 2A). SCC cells showed density-related
changes in Lam3 and Lam3 expression similar to
that of normal keratinocytes, but continued to express
Lam2 at high levels at confluence (Figure 2A). The
consequence of excess Lam2 expression in SCC cellswas revealed by nonreducing Western blots, which re-
solve laminin monomers from the disulfide-bonded het-
erodimer assembly intermediates and the ultimate
Lam332 trimer.62 Cell extracts of confluent normal kera-
tinocytes contained Lam2 and Lam3 monomers and
the 240 kDa Lam32 assembly intermediate, in addi-
tion to fully formed 440 kDa Lam332 trimer (Figure 2B).
In contrast, SCC cells contained mostly Lam2 and
Lam3 monomers and heterodimers, with little trimer
(Figure 2B), presumably the result of unbalanced subunit
expression (Figure 2A). Analysis of conditioned medium
(Figure 2C) revealed that normal keratinocytes secreted
Lam2 exclusively assembled into Lam332 trimers,
whereas a fraction of the total Lam2 in SCC conditioned
medium was in the form of monomers, both unprocessed
(155 kDa) and processed (105 kDa).63
Abnormal Laminin 2 Regulation Begins Early in
Neoplastic Progression as a Characteristic of
Premalignant Keratinocytes
In vivo, Lam2 overexpression begins in regions of
preinvasive dysplasias25 (Figure 1A). We therefore
Figure 2. Unbalanced Lam332 subunit expres-
sion by SCC cells and secretion of abnormal
assembly intermediates. A:Western blot analysis
of the three Lam332 subunits in low-density (L)
versus high-density (H) cultures of normal kera-
tinocytes (G5Ep, O5Ep, strain N) and SCC cells
(SCC-25, SCC-15, SCC-68). Note strong density
repression of Lam2 by normal keratinocytes
and lack of it by SCC cells. B: Nonreducing gels
of cell extracts of confluent normal keratinocyte
and SCC cultures Western blotted for Lam2
(upper gel) and Lam3 (lower gel). Note that
SCCs have little or no intracellular Lam332
trimer, compared with normal keratinocytes,
and that the Lam3 antibody does not bind well
to Lam3 after assembly into the Lam332 trimer
in normal cells. C: Nonreducing gels of condi-
tioned medium from confluent normal keratino-
cyte and SCC cultures Western blotted for
Lam2, disclosing relative proportions of normal
Lam332 trimer, 32 dimer, and Lam2 mono-
mer. Note secretion by SCC cells of Lam2
monomer in processed (105 kDa; 2) and un-
processed (155 kDa; 2=) forms.asked whether cells cultured from dysplasias display
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as is the case for SCC cells. The POE9n and D17 cell
lines cultured from human oral dysplasias30,38,39
proved to maintain Lam2 expression at confluence, in
contrast to the normal keratinocytes OKF6 and strain N
(Figure 3, A and B).
In certain stratified epithelia (ie, cervix, tonsil, and
vulva), early neoplastic development is sometimes linked
to infection with human papillomavirus (HPV) type 16 or
18, leading to integration of viral genomic DNA and ex-
pression of their E6 and E7 oncogenes.5–8 Normal pri-
mary keratinocytes (strain N) transduced to express
HPV16 E6 and E7 (the N/E6E7 cell line) maintained
Lam2 expression at confluence, similar to SCC cells
(Figures 1 and 2) and POE9n and D17 cells (Figure 3, A
and B).
Important activities of the HPV16 oncoproteins are to
target p53 for degradation (accomplished by the E6 on-
coprotein60) and to inactivate pRB and thereby confer
resistance to the CDK4 inhibitor p16INK4A (accomplished
by E764). We wished to determine whether loss of p53-
dependent and pRB/p16INK4A-dependent growth control
achieved by genetic alterations not involving viral onco-
genes, as is the case for most oral and epidermal SCCs,
would result in loss of normal Lam2 regulation. We
therefore assessed the Lam2 expression characteris-
tics of strain N keratinocytes engineered to express a
dominant-negative mutant p53 and a p16-insensitive
mutant cdk4 (N/p/c cells34) and found that N/p/c cellsreduced Lam2 expression at confluence similar to nor-
mal primary keratinocytes. This finding demonstrated that
activities of E6 and/or E7 other than disabling p53 or
pRB/p16INK4A functions are responsible for Lam2 dys-
regulation. Comparing the properties of strain N cells
engineered to express either E7 or E6 alone, we found
that E6 alone caused loss of Lam2 regulation (Figure
3B). Finally, examining the effects of expressing
E6(JH26), a mutant of E6 that lacks p53-targeting activity
but retains E6 transcriptional transactivation activity,58,60
we found that an activity of E6 other than p53 degradation
is responsible for Lam2 dysregulation (Figure 3B; see
also Supplemental Figure S2 available at http://ajp.
amjpathol.org). Notably, E6 activates transcription of a
variety of genes, including hTERT65,66 and EGFR,67,68
and has been reported recently to activate mTOR.69
Hyperactivity of Signaling Kinases Downstream
of EGFR Correlates with Lamin 2
Overexpression
Hyperactivity of the EGFR/(MAPK)ERK and PI3K/AKT/
mTOR pathways are frequent abnormalities of advanced
oral and oropharyngeal SCC.9–11 We sought to identify
signaling alterations in these two pathways (Figure 4A) in
confluent cultures of premalignant keratinocytes and
SCCs that correlate with Lam2 dysregulation. EGFR
Figure 3. Abnormal laminin 2 expression by
premalignant keratinocytes. A: Lam2 immuno-
fluorescence-stained confluent cultures of nor-
mal oral keratinocyte line OKF6, premalignant
dysplastic oral keratinocyte lines POE9n and
D17, normal epidermal keratinocyte line strain
N, and strain N transduced to express the HPV16
E6 and E7 oncoproteins (N/E6E7). Note contin-
ued Lam2 expression at confluence by POE9n,
D17, and N/E6E7 in contrast to repression of
Lam2 under this condition by normal keratino-
cytes. Scale bar  200 m. B: Left: Lam2 West-
ern blots of low-density (L) and high-density (H)
cultures of the same cell lines, confirming lack of
2 repression at confluence by POE9n, D17, and
N/E6E7. Right: Lam2 Western blots of N/E7,
N/E6, N/E6JH26, and of strain N transduced to
express a dominant-negative mutant p53 and a
p16INK4A-resistant mutant cdk4 (N/p/c), show-
ing that E6 alone can dysregulate Lam2, and
that functional loss of p53 is not involved in this
dysregulation. Densitometric quantification of
each band is shown below the blots. The Lam2
level (normalized to its actin band) of the pre-
confluent culture of each cell line is set as 1 (gray
bars), with the relative Lam2 level of the con-
fluent culture shown for each cell line (black
bars). Error bars indicate the results of quantify-
ing scans of two exposures of each gel. The error
bars show the results of the scans of two differ-
ent exposure times of the same Western blot.
The gray and black bars show the average of
these two scans.overexpression, accompanied by increased levels of the
Ku-0063
2 reduct
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lines that overexpressed Lam2 (Figure 4B). Levels of
p-ERK, a downstream target of EGFR activation mediated
by RAS, RAF, and MEK, also were elevated, compared
with normal cells, in all of the Lam2-overexpressing neo-
plastic cell lines, although not proportional to p-EGFR
levels (Figure 4B).
We also analyzed the phosphorylation states of AKT, a
signaling mediator in the PI3K/mTOR pathway, and of
S6, a downstream target of both EGFR/ERK and PI3K/
mTOR pathways. p-AKT was elevated in only three of the
six Lam2 dysregulated cell lines tested, but p-S6 was
substantially elevated in all of them (Figure 4B). The p-S6
antibody we used recognizes p-S6(ser235/236), which
can be phosphorylated either by the ERK-activated RSK
kinase or by the TORC1-activated S6 kinase (S6K1).70
We interpreted the lack of correlation between p-AKT and
p-S6 levels as indicating that S6 phosphorylation in
Lam2-overexpressing cells results from EGFR/ERK
pathway hyperactivity.
We next assessed the effects of small-molecule inhib-
Figure 4. Neoplastic cells that lack density-dependent Lam2 repression d
cascade signaling pathways and their downstream targets analyzed in this stu
a less important role for S6K1 in activating these targets. Note that S6K1 mus
S6 at ser(235/236). Underlining indicates proteins that were analyzed for ph
(shown in blue) were expressed or hyperactivated by engineering normal ke
B: Confluent cultures of normal (G5Ep, OKF6, strain N) and premalignant (N
by Western blotting for Lam2 and selected phosphoproteins. Note consiste
C: Effects of kinase inhibitors on Lam2 and Lam3 expression and on sig
preconfluent cultures of G5Ep were treated for 2 days with kinase inhibitor
gefitinib is an EGFR inhibitor, U0126 and AZD6244 are MEK inhibitors, and
Lam3 expression, by all kinase inhibitors tested except Ku-0063794. Lamitors of pathway kinases on Lam2 overexpression byPOE9n, NE6E7, and two SCC cell lines. The EGFR inhib-
itor gefitinib and the MEK inhibitors U0126 and AZD6244
substantially reduced p-ERK levels and Lam2 expres-
sion (Figure 4C). Gefitinib and U0126 greatly reduced
p-S6 levels in all four lines, although AZD6244 did not
affect S6 activation in POE9n and N/E6E7 (Figure 4C).
These results indicate that ERK-dependent RSK is the
major activator of S6. The TORC1/2 inhibitor Ku-0063794
greatly reduced p-S6 levels, but did not change Lam2
expression, revealing that S6 activation is not essential
for Lam2 overexpression (Figure 4C). S6K1 is thought to
phosphorylate S6 on ser235/236 and on ser240/244,
whereas the ERK-activated RSK phosphorylates S6 only
on ser235/236.71,72 Prior phosphorylation of S6 on
ser240/244 by S6K1 increases the ability of RSK to phos-
phorylate S6 on ser235/236.67 The reduction of
p-S6(ser235/236) levels by Ku-0063794 we observed is
consistent with those studies.
We also tested the effects of a TGF receptor I kinase
inhibitor, TRI, because the LAMC2 gene, which encodes
Lam2, is transcriptionally activated by TGF.73 As ex-
GFR/ERK hyperactivation. A: The EGFR/ERK and PI3K/AKT/mTOR kinase
ows indicate activation; T-bars indicate inhibition. Dashed arrows indicate
osphorylate S6 at ser(240/244) before either RSK or S6K1 can phosphorylate
lation/activation by Western blotting. For some experiments, some proteins
tes. Inhibitors that specifically block the associated kinase are shown in red.
OE9n, D17) keratinocytes and SCC cells (SCC-13, SCC-71, SCC-15) analyzed
FR, p-ERK, and p-S6 increases in all of the Lam2-overexpressing cell lines.
molecules. Confluent cultures of SCC-68, SCC-13, POE9n, and N/E6E7 and
en were analyzed by Western blotting. TRI is the TGF receptor I inhibitor,
794 is a TORC1/2 inhibitor. Note reduction of Lam2 expression, but not of
ion correlated consistently with decreased p-ERK.isplay E
dy. Arr
t first ph
osphory
ratinocy
/E6E7, P
nt p-EG
naling
s and thpected, TRI reduced Lam2 expression in all cell lines
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duced Lam3 expression (Figure 4C), consistent with the
lack of correlation between Lam2 and Lam3 expres-
sion in preconfluent and confluent normal keratinocytes
and SCC cells (Figure 2A).
Normal keratinocytes transiently overexpress Lam2
during wound re-epithelialization in vivo (see Supplemen-
tal Figure S3B at http://ajp.amjpathol.org).31,74,75 The ef-
fects of inhibitors on Lam2 expression and p-ERK and
p-S6 levels in preconfluent normal keratinocytes were the
same as for confluent premalignant and SCC cells (Fig-
ure 4C), demonstrating that Lam2 expression is ERK-
dependent in both normal and neoplastic settings.
Laminin 2 Expression in Neoplastic Cells Is
Regulated at the Level of Translation and
Correlates with the Activation States of
Translation Initiation Factors
ERK activation initially was found to have effects in the
nucleus, activating several transcriptional regulators, in-
cluding Elk-1.76 We used qPCR to investigate whether the
reduction of Lam2 protein expression caused by EGFR
and MEK inhibition (Figure 4C) is the result of reduced
LAMC2 gene transcription. Confluent SCC cultures treated
with EGFR or MEK inhibitors showed no substantial change
Figure 5. Lam2 overexpression by neoplastic cells is unrelated to Lam2 mR
A: Effects of kinase inhibitors on Lam2 mRNA levels in SCC cells. Confluent c
Ku-0063794 and then were analyzed by qPCR for Lam2 mRNA, with results for
mRNA levels resulting from treatment with TRI, but not with the EGFR inhibitor g
in confluent SCC cultures. B: qPCR comparison of Lam2 mRNA levels in preco
Results shown are relative to Lam2 mRNA levels in preconfluent cultures of st
neoplastic cells than in normal keratinocytes and absence of cell density-depend
blot analysis of activated forms of translation initiation factors in normal and pr
p-4E-BP1 in premalignant keratinocytes and SCC cells, compared with normal
cultures with kinase inhibitors on levels of Lam2, c-myc, and phosphorylated st
levels in response to the EGFR inhibitor gefitinib and the MEK inhibitors U0126
Western blot analysis of the effects on levels of Lam2 and p-eIF4B of 2-day treatments
treatment. Note that ERK and RSK inhibitors substantially reduced Lam2 and p-eIF4Bin Lam2 mRNA levels, compared with untreated controls
(Figure 5A). TRI reduced Lam2 mRNA levels to 40% of
control levels (Figure 5A), consistent with TRI effects on
Lam2 protein expression (Figure 4C) and confirming the
role of TGF signaling in Lam2 transcription.73
We next examined the density dependence of Lam2
mRNA levels. Lam2 mRNA levels in normal keratino-
cytes at confluence were 25% to 40% of that of precon-
fluent cells (Figure 5B), consistent with transcription or
mRNA stability playing a significant role in normal densi-
ty-related Lam2 repression. However, Lam2 mRNA
levels in premalignant and SCC cell lines did not change
between preconfluence and confluence and were typi-
cally lower than those of normal keratinocytes at conflu-
ence (Figure 5B). We concluded that Lam2 mRNA is
translated much more efficiently in neoplastic cells than
in normal cells at high cell density. In contrast, Lam3
mRNA decreased at confluence in both normal keratino-
cytes and SCC cells, and Lam3 mRNA slightly de-
creased in normal keratinocytes and increased in SCC
cells at confluence (see Supplemental Figure S4A at
http://ajp.amjpathol.org). This confirmed that the mecha-
nism regulating expression of Lam2 is different from the
mechanism or mechanisms regulating expression of the
other Lam332 subunits.
Translation initiation is the rate-limiting step for protein
synthesis. Efficient initiation requires translation initiation
ls, but correlates with ERK-dependent activation of translation initiation factors.
ere treated for 2 days with the inhibitors TRI, gefitinib, U0126, AZD6244, and
line internally normalized to GAPDHmRNA levels. Note the decrease in Lam2
r the MEK inhibitors U0126 and AZD6244, which block Lam2 protein synthesis
nd confluent cultures of normal and premalignant keratinocytes and SCC cells.
eratinocytes, set at an arbitrary unit of 1. Note lower levels of Lam2 mRNA in
A decreases in neoplastic cells, compared with normal keratinocytes. C:Western
nt keratinocytes and SCC cells. Note increased levels of p-eIF4B, p-eIF4E, and
cytes. D: Western blot analysis of effects of 2-day treatment of confluent SCC
anslation initiation factors. Note strong reduction of Lam2, c-myc, and p-eIF4B
6244, in contrast to small or no effect of the TORC1/2 inhibitor Ku-0063794. E:NA leve
ultures w
each cell
efitinib o
nfluent a
rain N k
ent mRN
emaligna
keratino
ates of tr
and AZDof confluent SCC cultures with ERK and RSK inhibitors, compared with U0126
levels.
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ulated by the EGFR/ERK and PI3K/mTOR signaling path-
ways71,77,78 (Figure 4A). We asked whether Lam2-over-
expressing neoplastic cells contain higher levels of the
phosphorylated active forms of any of these factors, com-
pared with normal cells. Western blot analysis of conflu-
ent cultures revealed higher levels of p-eIF4B, p-eIF4E,
and p-4E-BP1 in neoplastic cells than in normal keratino-
cytes (Figure 5C). The EGFR kinase inhibitor gefitinib and
the MEK inhibitors U0126 and AZD6244 greatly reduced
p-eIF4B and p-4E-BP1 levels and had a lesser effect on
p-eIF4E levels in SCC cells (Figure 5D). The TORC1/2
inhibitor Ku-0063794 greatly reduced p-4E-BP1 levels,
slightly reduced p-eIF4B levels, and had no effect on
p-eIF4E levels (Figure 5D). As expected, the TGFBRI
kinase inhibitor TRI had no effect on levels of any of these
phosphoproteins (Figure 5D).
The effects of these inhibitors on c-myc expression
proved to be the same as on Lam2 expression (Figure
5D). Expression of c-myc is regulated at the level of
translation by eIF4B/eIF4A, which aids translation initia-
tion of mRNAs having very long 5=-UTR sequences that
form stem-loop secondary structures.78,79 The Lam2 5=-
UTR proved to have such a long and complex structure,
similar to that of c-myc and much longer than those of
Lam3 and Lam3 mRNAs (see Supplemental Figure
S4B at http://ajp.amjpathol.org).
We extended our analysis by testing the effects of the
ERK1/2 inhibitor CAY1056149 and of the RSK inhibitor
BI-D1870.50 These inhibitors reduced Lam2 expression
associated with substantially reduced levels of p-S6 and
p-eIF4B (Figure 5E). These results are consistent with
ERK/RSK activation of p-eIF4B-dependent Lam2 mRNA
translation as the mechanism of Lam2 protein overex-
pression in neoplastic keratinocytes.
Hyperactive RAS, RAF, or MEK Signaling Is
Sufficient to Cause Abnormal Laminin 2
Expression
The above experiments clearly demonstrated that EGFR/
ERK/RSK activity is essential for Lam2 overexpression in
neoplastic cells. We wished to determine whether activation
of the EGFR/ERK signaling pathway in normal keratinocytes
is sufficient to cause loss of density-dependent Lam2 reg-
ulation. Our earlier study had revealed that primary kerati-
nocytes expressing activated HRAS grow well in the fibro-
blast feeder layer culture system, but undergo growth arrest
if switched to a semidefined keratinocyte medium,80 and
strain N and G5Ep primary keratinocyte lines transduced to
express HRAS(G12V) proved unable to proliferate in Ksfm
medium. Constitutively active mutant HRAS has been re-
ported to induce p16INK4A-enforced senescence in normal
cells under some conditions.56,81 For the following experi-
ments, therefore, we used our TERT-immortalized normal
keratinocyte line, N/TERT1,30 which is unable to express
p16INK4A or p14ARF but displays normal Lam2 repression
at confluence (Figure 6A).
N/TERT-1 cells transduced to express constitutively
active mutant forms of either EGFR, HRAS, cRAF1, orFigure 6. Hyperactivation of signaling pathway kinases upstream of ERK
results in Lam2 dysregulation in normal keratinocytes. A: Lam2 immu-
nostaining of confluent cultures of N/TERT-1 keratinocytes engineered to
express constitutively active HRAS(G12V), cRAF1(22w), or MEK1(DD),
and EGFR(E746-A750)-FLAG. Scale bar  200 m. B: Western blot
analysis of Lam2, signaling pathway phosphoproteins, and activation
state of translation initiation factors of the same cell lines. Control indi-
cates N/TERT-1 cells. Note that expression of constitutively active HRAS,
cRAF1, or MEK1 increased p-ERK, p-S6, and p-eIF4B levels, whereas
constitutively active EGFR slightly increased levels of p-ERK, robustly
increased p-S6, but did not increase p-eIF4B and did not cause Lam2
overexpression. C: Western blot analysis of effects of EGFR and MEK
inhibitors on Lam2 and p-ERK levels in control N/TERT-1 cells,
cRAF1(22w) and MEK1(DD) transductants, and SCC-13 cells. Note that
Lam2 overexpression and increased p-ERK levels in keratinocytes ex-
pressing activated mutant cRAF1 or MEK are normalized by treatment with
the MEK inhibitor AZD6244, but not with the EGFR kinase inhibitor
gefitinib.
panel),
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and proved to be independent of EGF for optimal growth
(see Supplemental Figure S5 at http://ajp.amjpathol.org).
This EGF independence was expected from the mutant
ras result of our previous study80 and confirmed the bio-
logical activity of all four EGFR signaling pathway mu-
tants in keratinocytes. Immunostaining and Western blot
analysis of confluent cultures revealed that the constitu-
Figure 7. Immunohistologic detection of Lam2 overexpression in vivo
premalignant dysplasias. In normal human oral mucosal epithelium (A), oral
sections were stained with H&E and immunostained for Lam2 and p-S6. En
insets, with the basal lamina traced by dotted lines. Scale bar  200 m.
Margin between normal epithelium (left half) and dysplasia (right half)
contrasting with Lam2 and basal cell p-S6 in the dysplastic region. C: Dysp
and the intensity of Lam2 immunostaining varies greatly. D: Region of a dy
overlying microinvasive SCC (indicated by arrowheads in the H&E-stained
Lam2 and basal p-S6 staining in areas of microinvasive SCC.tively active mutant forms of HRAS, cRAF1, and MEK1,but not of EGFR, conferred loss of density-dependent
Lam2 repression (Figure 6, A and C). We analyzed the
mutant cRAF1 and MEK1 transductants further by as-
sessing the effects of kinase inhibitors. As expected,
p-ERK levels and Lam2 expression in the cRAF1(22w)
and MEK1(DD) transductants were unaffected by ge-
fitinib inhibition of the upstream EGFR kinase, but were
reduced by AZD6244 inhibition of MEK (Figure 6C). Both
association with increased p-S6 and p-eIF4B levels in basal cells of oral
l dysplasias (B–D), and a microinvasive oral SCC arising from a dysplasia (E),
nts of the areas demarcated by small rectangles are shown as corresponding
al oral epithelium showing no Lam2 and only suprabasal p-S6 staining. B:
g no Lam2 and p-S6 confined to suprabasal cells in the normal region,
which not all basal cells are p-S6, not all p-S6 cells overexpress Lam2,
in which many basal cells are p-S6, but none express Lam2. E: Dysplasia
showing variable Lam2 and basal p-S6 staining in the dysplasia and strongand its
mucosa
largeme
A: Norm
, showin
lasia in
splasiainhibitors reduced Lam2 and p-ERK levels in SCC-13
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EGFR hyperactivity for ERK activation and consequent
Lam2 overexpression in this SCC cell line.
Having established that expression of either HRAS(G12V)
or cRAF1(22w) or MEK1(DD) is sufficient to cause Lam2
overexpression, we asked whether such oncogene-driven
ERK hyperactivation results in activation of the downstream
translation factors that we had found (as described above)
to correlate closely with ERK hyperactivity. Levels of
p-eIF4B and p-S6 proved to be elevated in the mutant
HRAS, cRAF1, and MEK1 transductants (Figure 6B). The
mutant EGFR transductant, which showed normal density
repression of Lam2, displayed a rather low level of p-ERK
activation and no increase in p-eIF4B. Its p-S6 levels, how-
ever, were increased to the same degree as in the mutant
HRAS, cRAF1, and MEK1 transductants (Figure 6B), sug-
gesting that lower levels of ERK activation are sufficient to
produce maximum p-S6. These results demonstrate that
ERK hyperactivation is sufficient to instigate neoplastic
Lam2 overexpression and provide further correlative evi-
dence that translation initiation factor activation produces
this response.
Basal Cells in Oral Dysplasias That Overexpress
Laminin 2 Have Elevated Levels of p-S6
Finally, we asked whether the abnormal activation of
ERK, translation factors, and S6 that we had identified in
premalignant dysplastic and SCC cells in culture is de-
tectable in vivo and correlates with Lam2 overexpres-
sion. We used immunostaining to examine a set of oral
dysplastic lesions, some of which included regions of nor-
mal epithelium as well as SCC. Lam2 was detectable in
basal cells of some regions in 23/26 dysplasias and 8/8
invasive SCCs, but was undetectable in normal oral epithe-
lium (Figure 7) or in two benign hyperplastic warts (see
Supplemental Figure S3A at http://ajp.amjpathol.org). Inten-
sity of Lam2 immunostaining varied among and within
specimens of dysplasia, without apparent relation to any
Figure 8. Association of Lam2 overexpression with increased basal cell
p-S6 levels in dysplastic lesions. Twenty-one oral lesions with dysplasia were
evaluated microscopically for the fraction of the dysplastic region of each that
contained p-S6 and Lam2 basal cells. Specimens were charted in order of
increasing percentage of Lam2 and p-S6, to better show the range of
immunostaining patterns.morphological features of the dysplasias (Figure 7). Thep-ERK, p-EIF4B, p-eIF4E, and p-4E-BP1 antibodies yielded
weak uniform staining or scattered suprabasal cell nuclear
staining and did not identify any differences among normal,
dysplastic, and SCC specimens (data not shown).
In contrast, the p-S6 antibody identified clear differ-
ences between normal and neoplastic epithelium, asso-
ciated with Lam2 overexpression. In normal epithelium
and benign warts, p-S6 immunostaining was always con-
fined to suprabasal cell layers (Figure 7; see also Sup-
plemental Figure S3A at http://ajp.amjpathol.org). In con-
trast, discontinuous basal cell p-S6 staining appeared in
20% to 100% of the dysplastic regions of 20/21 speci-
mens evaluated quantitatively (Figures 7 and 8). Lam2
immunostaining was always associated with basal p-S6
immunostaining, in a specific way. Regions containing
Lam2 cells always were within regions that contained
p-S6 basal cells. However, only a subfraction of the
basal p-S6 regions also contained Lam2 basal cells,
ranging from zero to 100% (Figures 7 and 8).
As reported previously,31,74,75 normal keratinocytes at
the edge of wounds or ulcers expressed Lam2 (see
Supplemental Figure S3B at http://ajp.amjpathol.org).
These regions also showed basal p-S6 immunostaining
(see Supplemental Figure S3B at http://ajp.amjpathol.
org), consistent with our finding that normal keratinocytes
in preconfluent cultures, which express Lam2, have
ERK-dependent increased p-S6 (Figure 4C). The dyspla-
sias we examined sometimes contained regions of ulcer-
ation or microerosion, in which the epithelium did not
completely cover the underlying connective tissue. The
Lam2/PS-6 immunostaining patterns of ulcerated re-
gions of dysplasia (see Supplemental Figure S3C at
http://ajp.amjpathol.org) resembled that of a wound edge
in normal epithelium, with Lam2 and basal cell p-S6
immunostaining. To avoid possible wound responses in
our quantitative immunostaining analysis (Figure 8), we
did not score regions of dysplasias within 20 cells of an
ulcer margin. We concluded from our analysis that immu-
nohistologically detectable increased p-S6 levels in basal
cells of dysplasias precede and accompany Lam2 over-
expression in vivo, consistent with a causal relationship
between ERK-dependent activation of translation factors
and Lam2 overexpression.
Discussion
The present study extends our earlier study identifying
Lam2 overexpression in many premalignant oral and
epidermal dysplasias,25 which had followed studies by
others finding Lam2 overexpression in advanced
SCCs.28,29 Here, we have investigated the mechanism of
neoplastic Lam2 overexpression using a set of normal
primary and premalignant human keratinocyte and SCC
lines that recapitulate in culture this difference in Lam2
regulation between normal and neoplastic epithelial cells.
ERK hyperactivity proved to be necessary and sufficient
to cause Lam2 overexpression, strongly correlating with
ERK-dependent phosphorylation and activation of the
translation factors S6 and eIF4B. Consistent with this
finding, neoplastic Lam2 overexpression in culture
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Our cell culture findings were confirmed by immunostain-
ing analysis of clinical material, which revealed increased
p-S6 preceding and accompanying Lam2 overexpres-
sion in the basal cell layer of oral dysplasias. Most im-
portantly, the present study identifies EGFR/ERK hyper-
activity and consequent Lam2 overexpression as a
rather early step during progression to SCC, occurring in
some regions of preinvasive dysplasias.
Laminin 2 Overexpression as an Indicator of
ERK Hyperactivity
Hyperactivity of the EGFR/ERK82–84 and PI3K/AKT/
mTOR11,85,86 signaling pathways is a frequent feature of
oral and oropharyngeal SCC. We found increased levels
of EGFR and of its activated, phosphorylated tyr1068
state in all of the SCC and premalignant cell lines we
tested. However, we found increased p-AKT levels in only
some SCC lines, consistent with a previous study,85 and
no increase of p-AKT in the premalignant lines. Small-
molecule inhibitors of the EGFR and MEK kinases
blocked Lam2 overexpression, but an mTORC1/2 inhib-
itor did not, supporting the conclusion that hyperactive
EGFR/ERK signaling is the cause of dysregulated Lam2
expression. Reinforcing this conclusion was our finding
that ERK hyperactivity achieved by engineering normal
keratinocytes to express constitutively active HRAS,
cRAF1, or MEK1 was sufficient to cause Lam2 overex-
pression. Activating HRAS gene mutations are found in
5% of human oral and oropharyngeal SCCs,86 and
amplifications of KRAS and ERK1(MAPK3) are occasion-
ally detected also,84 but EGFR overexpression is the
most frequent instigator of ERK hyperactivity in oral and
oropharyngeal SCCs.82–84
Engineered expression of a constitutively active EGFR
deletion mutant [EGFR(E746-A750)], cloned from a tra-
cheobronchial SCC,43 did not yield Lam2 overexpres-
sion, but resulted in a modest increase of p-ERK levels
and EGF independence for growth. This finding suggests
that ERK stimulation above a certain threshold is required
for the Lam2 phenotype, a hypothesis testable in future
experiments examining the effects of other activating
EGFR mutations. The E6 and E7 viral oncoproteins of
HPV16 and HPV18 initiate neoplastic progression in a
high percentage of tonsil/oropharynx SCCs, but are
rarely involved in oral cavity and epidermal SCC.6 Con-
sistent with reports that HPV16 E6, potentiated by E7,
increases EGFR levels and activation in keratino-
cytes,67,68 we found that primary keratinocytes engi-
neered to express E6 and E7 displayed hyperactive
EGFR and ERK and overexpressed Lam2.
The same system responsible for Lam2 overexpres-
sion in dysplasias and SCCs proved to be essential for
Lam2 expression in normal keratinocytes in preconflu-
ent cultures, when they are expressing high levels of
Lam2. Under this condition, the EGFR/ERK pathway
was active and S6 was phosphorylated in normal cells
(as expected, because the cells are grown with EGF as a
mitogen), and EGFR and MEK inhibitors repressed
Lam2 expression. This cell culture finding is a manifes-tation of the in vivo wound re-epithelialization response,
because we found that basal keratinocytes at normal
wound edges have increased Lam2 and p-S6 levels.
Neoplastic Overexpression of Laminin 2 and
eIF4B-Dependent Regulation of mRNA Translation
Consistent with a previous report of selective overexpres-
sion of the Lam2 subunit of Lam332 in carcinoma cells
in vivo,27 confluent cultures of premalignant keratinocytes
and SCC cells displayed ERK hyperactivity-dependent
Lam2 overexpression, whereas regulation of their
Lam3 and Lam3 expression was normal. In the pro-
cess of normal Lam332 assembly, 32 dimer formation
necessarily precedes the addition of Lam3 and ultimate
secretion of Lam332 trimer.62 Lam2 overexpression re-
sulted in abnormal secretion of Lam2 monomers, with
most of the Lam2 molecules remaining in the unpro-
cessed 155-kDa form. Basal epithelial cells adhere to
normally processed mature Lam332 by interaction of
64 integrin to the C-terminus of the Lam3 chain.2,41
We reported previously that Lam332 trimers having un-
processed Lam2 subunits induce sustained directional
motility in keratinocytes.31 Whether autocrine or para-
crine action of secreted Lam2 monomer or Lam332 with
unprocessed Lam2 produces any neoplastic phenotype
in vivo remains to be determined.
We were surprised to find from qPCR analysis that
neoplastic Lam2 overexpression is not the result of in-
creased mRNA levels. Transcription of the genes encod-
ing the three subunits of Lam332 is known to require
TGF pathway signaling,73 such that a TGFRI kinase
inhibitor greatly inhibits Lam2 expression at both the
protein level 31 and also the mRNA level (present study).
ERK activates transcriptional regulators in the nucleus,76
so we had expected that Lam2 gene expression might
be ERK-dependent. However, ERK activates the signal-
ing kinases RSK and MNK1 which, in turn, activate the
ribosomal protein S6 and several subunits of the cyto-
plasmic eIF4 complex required for translation initiation of
some mRNAs.77,78 eIF4E permits translation of mRNAs
that have the common 5= cap (also known as the m7G or
7-methylguanosine cap). eIF4E activity requires inactiva-
tion of the eIF4E inhibitor 4E-BP1 by TORC1-catalyzed
phosphorylation.87 In our experiments, the TORC1/2 inhib-
itor Ku-0063794 blocked 4E-BP1 phosphorylation, but had
no effect on Lam2 synthesis, ruling out an essential role for
eIF4E. Another protein of the eIF4 complex is eIF4B, an
essential activator of the eIF4A helicase, which unwinds and
opens mRNAs that have long 5=-UTRs with a densely hy-
drogen-bonded stem-loop structure. eIF4B must be phos-
phorylated to be active, and our kinase inhibitor experi-
ments revealed that this is accomplished primarily by the
ERK-dependent RSK kinase. In our experiments, p-eIF4B
levels proved to correlate most closely with the level of
Lam2 expression. MYCmRNA has a long and highly struc-
tured 5=-UTR and requires eIF4B activation for translation.79
The 5=-UTR of Lam2 mRNA has a similar length and struc-
ture, and our results clearly implicate eIF4B-dependent
translation initiation as the determining factor for Lam2
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whether the Lam2 5=-UTR imposes ERK/RSK-dependent
translation control on reporter constructs.
S6 Phosphorylation as a Biomarker of ERK
Hyperactivity in Neoplastic Keratinocytes
S6 is a component of the 40S ribosome subunit, and its
phosphorylation at ser235/236 appears to be important
under conditions that require very high rates of protein
synthesis and to ensure normal cell size.88 The high level
of p-S6(ser235/236) present in all of the SCC and prema-
lignant lines at confluence indicates that S6 kinases are
active in these cells. The S6(ser235/236) phosphoryla-
tion, essential for S6 activity, can be accomplished either
by TORC1-dependent S6K1 or by ERK-dependent
RSK.70 The relative importance of ERK-dependent and
TORC1-dependent kinases on S6 phosphorylation and
activation has been incompletely studied and may vary
among different cell types and circumstances. In a study
of HeLa cells, most S6(ser235/236) phosphorylation was
ERK-dependent.72 Little or no S6(ser235/236) phosphor-
ylation occurred in keratinocytes and SCC cells when
ERK activity was blocked by a MEK inhibitor, indicating
that in these cells the critical ser235/236 phosphorylation
is ERK-dependent. The ability of RSK to accomplish the
ser235/236 phosphorylation is greatly enhanced by prior
S6K1-catalyzed ser240/244 phosphorylation of S6.71,72
Treatment with the TORC1/2 inhibitor Ku-0063794 re-
sulted in complete absence of p-S6(ser234/235), consis-
tent with the precondition of TORC1-dependent S6K1
phosphorylation at ser(240/244). The absence of an ef-
fect of Ku-0063794 on Lam2 overexpression shows that
p-S6(ser235/236) levels are not limiting for Lam2 syn-
thesis. Despite being nonessential for Lam2 overex-
pression, high levels of p-S6(235/236) always accompa-
nied it in our cell culture systems in the absence of kinase
inhibitors. We found that p-S6(235/236) was the most
useful biomarker of signaling pathway hyperactivity as-
sociated with Lam2 overexpression in vivo.
Immunodetection of Abnormal p-S6 and
Laminin 2 in Clinical Specimens of Oral
Dysplasia
This initial analysis of signaling protein phosphorylation
status during oral epithelial neoplastic progression in vivo
has revealed the potential power of immunohistochemi-
cal staining for detecting signaling abnormalities that
may have diagnostic or prognostic value, as well as the
limitations. Cytoplasmic content of the secreted protein
Lam2 and the phosphorylated versions of signaling me-
diators are excellent candidates for biomarkers of neo-
plastic progression, because they indicate the current or
very recent physiological state of individual cells at the
time of fixation. Clinical and experimental utility depends,
of course, on reliable detectability. Phosphorylations of
signaling pathway proteins are subject to continual turn-
over, owing to their susceptibility to intracellular phospha-
tases.89,90 Current procedures for handling of biopsyand surgical specimens and for formalin fixation may
not consistently preserve the phosphorylated states of
some proteins. Several immunohistochemical analyses
of signaling pathway activation in tissue microarrays of
oropharyngeal SCCs have produced inconclusive re-
sults, owing to inconsistent, weak, and/or predominantly
differentiated cell staining for phosphoproteins and the
challenge of finding suitable criteria for quantifying the
results.91,92 As an integral ribosomal protein, S6 is much
more abundant, and its phosphorylated form may also be
more stable, than that of eIF4B and mediators of the
EGFR/ERK/RSK pathway.
p-S6 immunostaining proved to be intense, pre-
served in all archival pathology specimens we tested,
and showing clear differences between normal or hy-
perplastic versus dysplastic or SCC tissue. p-S6 was
readily detectable in suprabasal cell layers of normal
stratified epithelia, but not in the basal cell layer. In
contrast, periodic or continuous basal cell p-S6 was
detectable in portions of all but one of the dysplasias
examined, ranging from 20% to 100% of the length of
dysplastic regions, consistent with a previous study.93
We found that Lam2 overexpression was consistently
confined to a subfraction, ranging from zero to 100%,
of the basal p-S6 regions. There are at least two
explanations for this finding. First, levels of p-S6 (as a
surrogate for ERK hyperactivity and consequent eIF4B
activity) may fluctuate substantially in vivo and may
need to remain elevated continuously for a sufficiently
long time for enough Lam2 translation to occur to be
detectable. Second, increased p-S6(ser235/236) lev-
els may in some cases result from increased AKT/
mTOR activity instead of increased ERK/RSK activity,
but only the latter will result in increased Lam2 ex-
pression. We did not detect basal cell p-AKT by immu-
nostaining, which could have identified a role for AKT/
mTOR hyperactivity in p-S6/Lam2 regions.
The present study demonstrates that ERK hyperac-
tivity and consequent Lam2 overexpression begins
relatively early, in the preinvasive stages of oral epi-
thelial neoplastic progression. These results provide
the rationale for larger studies to seek correlations
between p-S6/Lam2 immunostaining patterns in dys-
plasias and future progression (and its time frame) to
invasive SCC. Such studies would aim to identify a
specific pattern or extent of p-S6 and Lam2 staining
that correlates with future SCC, thus providing a defin-
itive prognosis of dysplastic lesions. Our results also
support the idea of early EGFR or MEK kinase inhibitor
therapy for patients whose oral lesions have a high
probability of progressing to invasive SCC but cannot
be completely resected surgically without compromis-
ing function of the tongue. Clinical studies to date
using targeted kinase inhibitors systemically for treat-
ment of advanced SCC have yielded modest or tem-
porary responses and serious side effects.12,94 Prein-
vasive lesions at high risk of malignant progression,
and of relatively small total mass, may be more ame-
nable to complete cure by local and/or short-term ki-
nase inhibitor treatment.
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